NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

March 1, 2027

Study Completion Date

June 30, 2027

Conditions

Chronic Hepatitis b

Interventions

BIOLOGICAL

Therapeutic hepatitis B vaccine

HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant

BIOLOGICAL

Commercial Hepatitis B vaccine

Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant

Trial Locations (1)

ARASMI, Adelaide

All Listed Sponsors

collaborator

Australian Respiratory and Sleep Medicine Institute

OTHER

lead

Vaxine Pty Ltd

INDUSTRY